← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Neuphoria Therapeutics Inc. (NEUP) 10-Year Financial Performance & Capital Metrics

NEUP • • Industrial / General
HealthcarePharmaceuticalsBiopharmaceutical R&DMental Health Therapeutics
AboutNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.Show more
  • Revenue $24M
  • EBITDA -$714K +97.2%
  • Net Income -$566K +97.6%
  • EPS (Diluted) -0.23 -130.0%
  • Gross Margin 95.76%
  • EBITDA Margin -2.98%
  • Operating Margin -7.21%
  • Net Margin -2.36%
  • ROE -0.01% +100.0%
  • ROIC -0.05% +100.0%
  • Debt/Equity 0.01 -60.7%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong Piotroski F-Score: 8/9
  • ✓FCF machine: 322.4% free cash flow margin
  • ✓Strong 5Y sales CAGR of 250.7%
  • ✓Share count reduced 98.9% through buybacks
  • ✓Trading at only 0.0x book value

✗Weaknesses

  • ✗Weak momentum: RS Rating 10 (bottom 10%)
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y12.61%
5Y250.73%
3Y341.74%
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-2244.37%

EPS CAGR

10Y-
5Y-
3Y-
TTM84.15%

ROCE

10Y Avg-57.95%
5Y Avg-63.78%
3Y Avg-67.8%
Latest-0.01%

Peer Comparison

Mental Health Therapeutics
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CMPSCOMPASS Pathways plc701.88M7.31-3.18-6.31%0.21
ATAIAtai Beckley N.V1.35B3.71-3.99-1.91%-51.09%-96.43%0.21
NEUPNeuphoria Therapeutics Inc.22.05M4.10-17.83-40.76%-30.24%100%0.01

Profit & Loss

Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Sales/Revenue+7.79M18.17M3.95M717.53K45.13K0277.89K0023.95M
Revenue Growth %0.07%1.33%-0.78%-0.82%-0.94%-1%--1%--
Cost of Goods Sold+000001.69M0671.42K992.56K1.01M
COGS % of Revenue---------0.04%
Gross Profit+00000-1.69M0-671.42K-992.56K22.94M
Gross Margin %---------0.96%
Gross Profit Growth %------1%--0.48%24.11%
Operating Expenses+34.21M30.3M32.68M19.34M9.36M11.26M27.71M21.58M25.79M24.67M
OpEx % of Revenue4.39%1.67%8.27%26.96%207.29%-99.71%--1.03%
Selling, General & Admin10.05M6.44M6.11M6.94M3.72M5.53M10.84M8.35M11.69M10.88M
SG&A % of Revenue1.29%0.35%1.55%9.67%82.39%-39.03%--0.45%
Research & Development24.16M23.85M26.57M12.41M5.64M5.73M16.86M13.23M14.1M13.78M
R&D % of Revenue3.1%1.31%6.73%17.29%124.9%-60.69%--0.58%
Other Operating Expenses0000000000
Operating Income+-28.31M-13.85M-30.48M-20.37M-11.67M-12.95M-28.6M-22.26M-26.79M-1.73M
Operating Margin %-3.63%-0.76%-7.72%-28.39%-258.66%--102.92%---0.07%
Operating Income Growth %0.02%0.51%-1.2%0.33%0.43%-0.11%-1.21%0.22%-0.2%0.94%
EBITDA+-26.42M-12.13M-28.73M-18.63M-9.31M-11.26M-27.43M-21.58M-25.79M-713.59K
EBITDA Margin %-3.39%-0.67%-7.27%-25.96%-206.29%--98.71%---0.03%
EBITDA Growth %0.02%0.54%-1.37%0.35%0.5%-0.21%-1.44%0.21%-0.2%0.97%
D&A (Non-Cash Add-back)1.89M1.72M1.76M1.75M2.36M1.69M1.17M671.42K992.56K1.01M
EBIT-24.46M-11.14M-32.72M-14.8M-6.89M-8.32M-29.2M-22.22M-23.32M-1.28M
Net Interest Income+-498.64K-589K-1.09M-1.46M-1.2M-1.07M-11.7K323.16K220.1K166.5K
Interest Income915.95K925.02K422.32K197.95K39.13K4.29K6.79K323.16K220.1K166.5K
Interest Expense1.41M1.51M1.51M1.66M1.24M1.08M18.48K000
Other Income/Expense2.16M918.89K-4.05M2.95M3M3.19M-642.61K39.87K3.46M445.56K
Pretax Income+-26.16M-12.93M-34.53M-17.42M-8.68M-9.76M-29.24M-22.22M-23.32M-1.28M
Pretax Margin %-3.36%-0.71%-8.74%-24.28%-192.29%--105.23%---0.05%
Income Tax+-9.98M-6.28M-8.13M-6.78M-3.05M-1.11M-6.31M-568.89K-130.73K-716.9K
Effective Tax Rate %0.62%0.51%0.76%0.61%0.79%0.89%0.78%0.97%0.99%0.44%
Net Income+-16.18M-6.65M-26.4M-10.6M-6.89M-8.65M-22.94M-21.65M-23.19M-565.77K
Net Margin %-2.08%-0.37%-6.68%-14.77%-152.56%--82.54%---0.02%
Net Income Growth %0.13%0.59%-2.97%0.6%0.35%-0.26%-1.65%0.06%-0.07%0.98%
Net Income (Continuing)-16.18M-6.65M-26.4M-10.64M-5.63M-8.65M-22.94M-21.65M-23.19M-565.77K
Discontinued Operations00042.19K-1.26M00000
Minority Interest0000000000
EPS (Diluted)+-0.33-0.13-0.46-0.16-0.11-0.10-0.13-0.17-0.10-0.23
EPS Growth %0.11%0.61%-2.54%0.65%0.31%0.09%-0.3%-0.31%0.41%-1.3%
EPS (Basic)-0.33-0.13-0.46-0.16-0.11-0.10-0.13-0.17-0.10-0.23
Diluted Shares Outstanding38.1M40.11M40.19M43.44M45.41M65M112.78M122.39M149.8M1.62M
Basic Shares Outstanding38.1M40.11M40.19M43.44M45.41M65M112.78M122.39M149.8M1.62M
Dividend Payout Ratio----------

Balance Sheet

Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Current Assets+43.38M41.86M26.39M17.6M5.73M23.24M28.76M8.87M13.19M15.04B
Cash & Short-Term Investments34.35M33.37M18.72M10.18M3.15M21.41M23.09M8.06M12.61M14.21B
Cash Only33.94M32.95M18.31M9.79M3.15M21.41M23.09M8.06M12.61M14.21B
Short-Term Investments410.73K422.65K404.02K385.19K000000
Accounts Receivable8.22M7.6M523.5K621.02K40.74K192.88K4.67M283.62K126.88K11.95M
Days Sales Outstanding385.05152.7348.38315.91329.46-6.13K--182.06
Inventory327.73K327.16K360.02K465.4K000000
Days Inventory Outstanding----------
Other Current Assets2492.02K6.09M5.49M2.01M984.28K00351817.4M
Total Non-Current Assets+22.35M22.74M21.41M19.98M17.95M17.53M16.17M10.52M14.46M13.55B
Property, Plant & Equipment2.12M2.01M2.02M1.76M724.9K654.37K464.01K221.66K218.97K105.38M
Fixed Asset Turnover3.68x9.03x1.96x0.41x0.06x-0.60x--0.23x
Goodwill7.95M9.42M9.16M8.94M8.84M9.32M8.85M5.79M8.69M8.64B
Intangible Assets12M11.01M9.95M9.02M8.08M7.47M6.77M4.08M5.47M4.8B
Long-Term Investments286.76K295.08K282.08K384K436.17K119K052.52K78.83K0
Other Non-Current Assets000-115.07K-136.47K-29.59K81.86K0-7950
Total Assets+65.72M64.61M47.8M37.58M23.68M40.77M44.93M19.39M27.65M28.59B
Asset Turnover0.12x0.28x0.08x0.02x0.00x-0.01x--0.00x
Asset Growth %0.24%-0.02%-0.26%-0.21%-0.37%0.72%0.1%-0.57%0.43%1033.02%
Total Current Liabilities+8.5M10.67M9.76M9.67M5.68M1.77M2.31M1.82M3.83M4.22B
Accounts Payable1.97M1.46M2.65M842.3K866.78K772.93K1.07M958.06K2.24M1.15B
Days Payables Outstanding-----166.83-520.83825.2415.26K
Short-Term Debt2.89M6.53M4.29M5.92M3.56M0097.9K33.12K116.31M
Deferred Revenue (Current)49.15K14.99K64.17K158.09K000000
Other Current Liabilities1.19M1.31M1.1M654.1K267.17K279.45K281.57K385.59K328.89K2.95B
Current Ratio5.10x3.92x2.70x1.82x1.01x13.10x12.46x4.87x3.45x3.56x
Quick Ratio5.06x3.89x2.67x1.77x1.01x13.10x12.46x4.87x3.45x3.56x
Cash Conversion Cycle----------
Total Non-Current Liabilities+25.53M22.85M25.58M15.52M9.28M3.23M3.47M2.92M6.33M5.37B
Long-Term Debt13.77M7.69M11.56M6.06M4.3M00000
Capital Lease Obligations000017.48K521.14K367.06K159.65K117.63K0
Deferred Tax Liabilities3.78M3.67M2.21M2.06M1.51M1.38M1.24M1.11M963.54K495.11M
Other Non-Current Liabilities7.99M11.49M11.81M7.4M3.45M1.33M1.86M1.64M5.25M4.87B
Total Liabilities34.04M33.52M35.34M25.18M14.97M5.01M5.78M4.74M10.16M9.59B
Total Debt+16.66M14.22M15.85M11.98M8.41M652.04K477.15K257.55K272.74K116.31M
Net Debt-17.28M-18.72M-2.47M2.18M5.26M-20.76M-22.61M-7.8M-12.34M-14.09B
Debt / Equity0.53x0.46x1.27x0.97x0.96x0.02x0.01x0.02x0.02x0.01x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-20.01x-9.14x-20.17x-12.30x-9.43x-12.02x-1547.24x---
Total Equity+31.69M31.09M12.46M12.39M8.71M35.76M39.15M14.65M17.49M19B
Equity Growth %0.29%-0.02%-0.6%-0.01%-0.3%3.1%0.09%-0.63%0.19%1085.48%
Book Value per Share0.830.770.310.290.190.550.350.120.1211708.85
Total Shareholders' Equity31.69M31.09M12.46M12.39M8.71M35.76M39.15M14.65M17.49M19B
Common Stock100.36M103.38M99.33M101.51M101.8M142.9M149.75M0019K
Retained Earnings-77.05M-83.14M-96.49M-98.65M-102.3M-115.74M-119.22M-108.16M-177.98M-178.35B
Treasury Stock0000000000
Accumulated OCI8.38M10.85M9.62M9.54M9.22M8.6M8.62M3.2M-3.01M-2.85B
Minority Interest0000000000

Cash Flow

Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Cash from Operations+-15.36M-1.44M-15.02M-10.91M-2.68M-5.66M-14.97M-9.85M-14.68M77.23M
Operating CF Margin %-1.97%-0.08%-3.8%-15.21%-59.42%--53.85%--3.22%
Operating CF Growth %-4.11%0.91%-9.43%0.27%0.75%-1.11%-1.64%0.34%-0.49%6.26%
Net Income0000-4.89M-6.53M-14.97M-14.38M-15.49M-369.63M
Depreciation & Amortization00001.68M1.28M763.17K446.09K662.99K662.89M
Stock-Based Compensation000038.03K983.01K1.95M0814.81K163.77M
Deferred Taxes000000000-468.43M
Other Non-Cash Items-15.36M-1.44M-15.02M-10.91M-2.28M-2.62M1.15M1.01M-2.12M89.12M
Working Capital Changes-1.45M970.52K63.96K-480.02K2.77M1.23M-3.85M3.08M1.46M-496.83K
Change in Receivables00002.71M1.52M-4.01M2.78M299.2K114.94K
Change in Inventory0000-19.44K00000
Change in Payables0000000251.69K804.37K-917.66K
Cash from Investing+824.64K733.05K59.68K138.42K-134.08K-60.26K427.68K000
Capital Expenditures-146.9K-190.2K-358.11K-69.28K-5.29K-1.1K-1.06K000
CapEx % of Revenue0.02%0.01%0.09%0.1%0.12%-0%---
Acquisitions----------
Investments----------
Other Investing971.53K923.25K417.79K207.71K221.76K29.85K129.06K000
Cash from Financing+24.79M-1.6M1.94M3.05M-3.68M23.71M18.57M2.6M15.11M1.53B
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing000-294.4K-226.68K-312.17K-3.94M05M1.53B
Net Change in Cash----------
Free Cash Flow+-11.62M-1.3M-15.38M-10.98M-2.69M-5.67M-14.97M-9.85M-14.68M77.23M
FCF Margin %-1.49%-0.07%-3.89%-15.31%-59.54%--53.86%--3.22%
FCF Growth %-4.7%0.89%-10.86%0.29%0.76%-1.11%-1.64%0.34%-0.49%6.26%
FCF per Share-0.30-0.03-0.38-0.25-0.06-0.09-0.13-0.08-0.1047.59
FCF Conversion (FCF/Net Income)0.95x0.22x0.57x1.03x0.39x0.66x0.65x0.45x0.63x-136.50x
Interest Paid1.7M1.95M1.93M1.93M1.34M726.42K0000
Taxes Paid065.68K00000000

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-57.58%-21.18%-121.24%-85.29%-65.24%-38.88%-61.23%-80.47%-144.32%-0.01%
Return on Invested Capital (ROIC)-142.08%-77.57%-204.56%-124.41%-61.33%-67.02%-136.02%-142.72%-334.63%-0.05%
Gross Margin---------95.76%
Net Margin-207.75%-36.58%-668.33%-1477.09%-15255.78%--8253.62%---2.36%
Debt / Equity0.53x0.46x1.27x0.97x0.96x0.02x0.01x0.02x0.02x0.01x
Interest Coverage-20.01x-9.14x-20.17x-12.30x-9.43x-12.02x-1547.24x---
FCF Conversion0.95x0.22x0.57x1.03x0.39x0.66x0.65x0.45x0.63x-136.50x
Revenue Growth6.66%133.25%-78.26%-81.83%-93.71%-100%--100%--

Frequently Asked Questions

Growth & Financials

Neuphoria Therapeutics Inc. (NEUP) reported $9.3M in revenue for fiscal year 2025. This represents a 74% increase from $5.3M in 2012.

Neuphoria Therapeutics Inc. (NEUP) grew revenue by 0.0% over the past year. Growth has been modest.

Neuphoria Therapeutics Inc. (NEUP) reported a net loss of $378.3M for fiscal year 2025.

Dividend & Returns

Neuphoria Therapeutics Inc. (NEUP) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.

Neuphoria Therapeutics Inc. (NEUP) generated $77.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.